Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05612438
Other study ID # P12204
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 3, 2023
Est. completion date August 30, 2023

Study information

Verified date November 2022
Source CID S.p.A.
Contact Franco Vallana, MD
Phone +39 0161 18261
Email franco.vallana@alvimedica.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Carbostent™ Radix 2 stent is a CE marked balloon expandable bare metal stent for the treatment of renal artery stenosis. The aim of this post-market retrospective study protocol P12204, is to collect clinical data on patients treated with the RADIX 2 stent in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Radix 2 stent at least 12 months prior to the study start.


Description:

The objective of this post-market study is collect retrospective clinical data on the implantable medical device Radix 2 stent in an unselected population treated in the current clinical practice. Data will be collected via medical chart review in anonymous form. Radix2 is a bare metal balloon expandable stent with a progressive multicellular design for treatment of renal artery stenosis. The stent is stent coated with i-Carbofilm™ to accelerate the rate of endothelization and strut coverage. The product is CE marked and commercially available since July 2010. Additional technical information on RADIX2 is available online: http://www.alvimedica.com/Product/15/bms-b-e-radix2


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date August 30, 2023
Est. primary completion date July 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: The study will be conducted in the "real world" population, according to the following criteria. Selection criteria: - Patient has been implanted with at least one study stent (Radix2) according to the indications described in the IFU. - Study Device Implanted is at least12 months prior to the starting date of the retrospective anonymous data collection. Exclusion Criteria: - Patients treated less than 12 months prior to study start

Study Design


Intervention

Device:
RADIX 2 Stent
RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis > 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.

Locations

Country Name City State
Italy Centro Cardiologico Monzino Milano

Sponsors (2)

Lead Sponsor Collaborator
CID S.p.A. Meditrial Europe Ltd.

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Zeller T, Rastan A, Kliem M, Schwarzwälder U, Frank U, Bürgelin K, Schwarz T, Amantea P, Müller C, Neumann FJ. Impact of carbon coating on the restenosis rate after stenting of atherosclerotic renal artery stenosis. J Endovasc Ther. 2005 Oct;12(5):605-11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Major renal events Major renal events at 30 days - composite of:
death from renal causes, related to study device or procedure; embolic events related to study device or procedure, resulting in kidney damage; acute kidney injury Stage 3 (AKIN criteria); ipsilateral nephrectomy, related to the study device or procedure.
30 days
Secondary Acute device success Acute Device Success, defined as the successful delivery of the assigned device(s) to the designated target location 24 hours
Secondary Technical success Technical Success, defined as the ability to implant the stent with a residual angiographic stenosis no greater than 30% 24 hours
Secondary In Stent Restenosis Restenosis of Radix2 stent, requiring repeat revascularization 12 months
Secondary Arterial Blood Pressure Systolic and diastolic arterial blood pressure changes during follow-up 12 months
See also
  Status Clinical Trial Phase
Completed NCT02763410 - Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Completed NCT03292029 - Pilot Medical Evaluation of the T50 Test N/A
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Completed NCT03806998 - Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure Phase 3
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT02116270 - Accelerated Immunosenescence and Chronic Kidney Disease N/A
Completed NCT01388270 - Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis Phase 4
Completed NCT01859273 - Adherence Enhancement for Renal Transplant Patients N/A
Completed NCT01187953 - Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx Phase 3
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01008631 - The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers N/A
Completed NCT00765661 - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients Phase 2
Completed NCT00737672 - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis Phase 3
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Recruiting NCT00470769 - The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR N/A
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2